TICKERNERD
Menu
ZBIOZBIOHealthcare · Biotechnology

ZBIO Stock Forecast: Zenas BioPharma, Inc. Price Predictions for 2026-2027

Last close, 14 Oct 2026
$25
−1.19% on the day

The 8 Wall Street analysts covering Zenas BioPharma, Inc. hold a median 12-month price target of $47 — +87.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 21 of 100 as at 14 Oct 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$1.6B
Ticker Nerd rank
21 / 100
Median analyst target
$47
Analysts covering
8
Revenue$1.0M
Operating income−$77.7M
Net income−$111.5M
Free cash flow−$87.2M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−11.8%
1M
−22.1%
YTD
−31.5%
1Y
−3.8%
From 52W high
−42.4%
From 52W low
+63.6%
$15
$43
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ZBIO stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Zenas BioPharma, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 14 Oct 2026
21 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
74
Value
55
Accruals
45
Size
38
Revisions
36
Volatility
32
Quality
31
Growth
27
Issuance
6

Momentum (74): The shares have been drifting up relative to others.

Issuance (6): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ZBIO stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ZBIO, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$20$30$40$50$60Jan 26Apr 26Jul 26Oct 26ZBIOHigh $59Median $47Low $32

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says8 analysts
7 Buy1 Hold0 Sell
Low $32Median $47High $59

The green dot is the last close — the median target sits +87.0% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 3 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
13 Oct 2026HC Wainwright & Co.ReiteratesBuy$44
30 Sept 2026CitigroupMaintainsBuy$41 → $48
30 Sept 2026HC Wainwright & Co.ReiteratesBuy$44
30 Sept 2026WedbushReiteratesOutperform$45
14 Aug 2026GuggenheimReiteratesBuy—
14 Aug 2026GuggenheimReiteratesBuy$55
14 Aug 2026Morgan StanleyMaintainsEqual-Weight$22 → $32
14 Aug 2026Morgan StanleyMaintainsEqual-Weight—
14 Aug 2026WedbushReiteratesOutperform—
14 Aug 2026WedbushReiteratesOutperform$45
15 May 2026HC Wainwright & Co.ReiteratesBuy$44
15 May 2026HC Wainwright & Co.ReiteratesBuy—
14 May 2026Morgan StanleyMaintainsEqual-Weight—
14 May 2026Morgan StanleyMaintainsEqual-Weight$21 → $22
17 Mar 2026CitigroupMaintainsBuy—
17 Mar 2026GuggenheimMaintainsBuy—
17 Mar 2026HC Wainwright & Co.ReiteratesBuy—
17 Mar 2026Morgan StanleyMaintainsEqual-Weight—
10 Feb 2026HC Wainwright & Co.ReiteratesBuy—
6 Jan 2026Morgan StanleyDowngradeEqual-Weight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ZBIO appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

ZBIO vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 14 Oct 2026, Zenas BioPharma, Inc. returned −3.8% against +17.5% for the S&P 500, dividends included.

ZBIO vs S&P 500, last 12 monthsTotal return, rebased to 100
6080100120140160180Jan 26Apr 26Jul 26Oct 26ZBIOS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ZBIO analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
2
Fundamentals

Zenas BioPharma, Inc. (ZBIO) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
1.6×

Cheaper than 70% of US stocks

Price / sales
1639.8×

Cheaper than 1% of US stocks

Price / book
6.4×

Cheaper than 15% of US stocks

EV / EBITDA
−4.7×

Cheaper than 80% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
−100.0%

Higher than 1% of US stocks

Gross margin
—
Operating margin
−7765.9%

Higher than 2% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−199.0%

Higher than 7% of US stocks

Return on assets
−34.4%

Higher than 12% of US stocks

Dividend yield
0.0%

Higher than 62% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Zenas BioPharma, Inc. (ZBIO) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Zenas BioPharma, Inc. has a market value of $1.6B and an enterprise value of $1.3B.

  • Revenue in the twelve months to 30 June 2026: $1.0M.

  • Net income over the same four quarters: −$484.4M, a −48438.4% net margin.

  • Diluted earnings per share, trailing twelve months: $−8.99.

  • Free cash flow in the twelve months to 30 June 2026: −$291.0M.

  • Shares outstanding: 63.3M.

  • Trailing P/E: 1.6×; forward P/E: −5.4× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.03%, paying out 0% of earnings.

  • Zenas BioPharma, Inc. employs 167 people — $6K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 14 Oct 2026

Data provided by Twelve Data

Peers

ZBIO vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ZBIOZenas BioPharma, Inc.$1.6B
21
INVAInnoviva, Inc.$1.6B
88
KRSAKorsana Biosciences, Inc.$1.6B
47
OCULOcular Therapeutix, Inc.$1.6B
37
BHVNBiohaven Ltd.$1.6B
32
GENBGenerate Biomedicines, Inc.$1.6B
1
NTLAIntellia Therapeutics, Inc.$1.6B
54

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Zenas BioPharma, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ZBIO news & analysis

Zenas BioPharma Announces Upcoming Presentations of Orelabrutinib Data in Relapsing Remitting Multiple Sclerosis, Clinical Trial Designs in Progressive Multiple Sclerosis and Other Multiple Sclerosis Portfolio Data at MSToronto2026

GlobeNewsWire · 7 Oct 2026neutral

Zenas BioPharma announced it will present seven posters at the 10th Joint ACTRIMS-ECTRIMS Meeting (MSToronto2026), scheduled for October 21–23, 2026, in Toronto. Topics include orelabrutinib data in relapsing-remitting multiple sclerosis, progressive MS trial designs, and other MS portfolio data.

Why it matters — The presentations will share updates on Zenas’s multiple sclerosis research and clinical trial plans with meeting attendees.

Zenas BioPharma to Host Virtual R&D Event

GlobeNewsWire · 6 Oct 2026neutral

Zenas BioPharma announced it will host a virtual R&D event on October 27, 2026, from 8:00 to 9:30 a.m. ET.

Why it matters — ZBIO watchers may note the scheduled event as an opportunity to hear about the company’s research and development.

Zenas BioPharma: Obexelimab Is Being Graded On The Wrong Curve

Seeking Alpha · 5 Oct 2026positive

Zenas BioPharma is advancing obexelimab for IgG4-RD, with FDA acceptance and a May 2027 PDUFA date, positioning it as a long-term maintenance therapy. The company maintains a sizable cash runway covering operations into late 2028, though financing risk remains if FDA approval is delayed.

Why it matters — A ZBIO watcher would care because obexelimab's non-depleting B cell inhibition offers a differentiated safety profile versus Uplizna, targeting chronic use in older patients and potentially expanding the addressable market.

Zenas BioPharma, Inc. (ZBIO) Discusses Obexelimab Prelaunch Strategy and Commercial Opportunity in IgG4-Related Disease Transcript

Seeking Alpha · 30 Sept 2026neutral

Zenas BioPharma discussed its prelaunch strategy for obexelimab and the commercial opportunity in IgG4-related disease during a presentation. The transcript covers the company's plans and market considerations for the therapy.

Why it matters — ZBIO watchers would care because the discussion outlines the company's commercial approach for its lead product candidate obexelimab ahead of a potential launch.

Zenas BioPharma Announces Upcoming Presentations of Obexelimab Data in IgG4-Related Disease at the IgG4ward! 6th International Symposium on IgG4-Related Disease and ACR Convergence 2026

GlobeNewsWire · 22 Sept 2026positive

Zenas BioPharma announced upcoming presentations of obexelimab data in IgG4-related disease at the IgG4ward! 6th International Symposium and ACR Convergence 2026. The presentations will include new data from the Phase 3 INDIGO open-label extension covering longer-term flare protection and safety.

Why it matters — The new longer-term efficacy and safety data from the INDIGO open-label extension could provide ZBIO watchers with additional insight into obexelimab's durability in treating IgG4-RD.

FAQ

Frequently asked questions about ZBIO stock

What is the ZBIO stock price forecast for 2026-2027?

The 8 Wall Street analysts covering Zenas BioPharma, Inc. have a median 12-month price target of $47, with estimates ranging from $32 to $59. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ZBIO stock a buy right now?

Of the 8 analysts covering Zenas BioPharma, Inc., 7 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Zenas BioPharma, Inc. 21 out of 100 across roughly 4,600 US stocks as at 14 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ZBIO?

As at 14 Oct 2026, Zenas BioPharma, Inc. ranks 21 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (74 of 100).

Will ZBIO stock go up?

No one can know that. What the data says: the median 12-month target from 8 analysts implies +87.0% from the last close, and Ticker Nerd's factor model ranks Zenas BioPharma, Inc. 21 out of 100 as at 14 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ZBIO stock forecast for 2030?

No analyst covering Zenas BioPharma, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ZBIO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $32 to $59 over the next 12 months.

How has ZBIO stock performed over the past year?

Zenas BioPharma, Inc. returned -3.8% over the 12 months to 14 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Zenas BioPharma, Inc. do?

Zenas BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing immunology-based therapies for autoimmune and inflammatory diseases.

What is the latest news on ZBIO?

The most recent item we track (GlobeNewsWire, 7 Oct 2026): "Zenas BioPharma Announces Upcoming Presentations of Orelabrutinib Data in Relapsing Remitting Multiple Sclerosis, Clinical Trial Designs in Progressive Multiple Sclerosis and Other Multiple Sclerosis Portfolio Data at MSToronto2026". Zenas BioPharma announced it will present seven posters at the 10th Joint ACTRIMS-ECTRIMS Meeting (MSToronto2026), scheduled for October 21–23, 2026, in Toronto. Topics include orelabrutinib data in relapsing-remitting multiple sclerosis, progressive MS trial designs, and other MS portfolio data.

Company

About Zenas BioPharma, Inc.

Zenas BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing immunology-based therapies for autoimmune and inflammatory diseases. The company’s lead program is obexelimab, a bifunctional monoclonal antibody being studied across multiple immune-mediated conditions, including IgG4-related disease, multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia. Zenas BioPharma also advances a broader pipeline of antibody-based and targeted therapies aimed at modulating immune pathways involved in chronic autoimmune disorders. Based in Waltham, Massachusetts, the company operates as a research-driven drug developer with current activities centered on clinical development, regulatory progress, and building a portfolio of therapies for patients with significant unmet medical needs.

CEO Mr. Leon Oliver Moulder Jr., M.B.A. · 167 employees · United States · https://zenasbio.com